The 17th edition of CTAD took place in Madrid from October 29 to November 1 of this year, where several Ace representatives attended to present their recent studies on Alzheimer’s disease.

Ace Alzheimer Center Barcelona presents its advances at CTAD 2024 in Madrid

The Ace Alzheimer Center Barcelona team participated in the 17th edition of CTAD 2024 (Clinical Trials on Alzheimer's Disease) held in Madrid between October 29 and November 1 this year, highlighted by its innovative contributions in the field of Alzheimer's research. The event brought together international experts, making it a key venue for sharing the latest advances in diagnostics and treatments for this disease.

Ace was represented by Dr. Mercè Boada, medical director; Miren Jone Gurrutxaga, general director; Dr. Juan Pablo Tartari, neurologist; Dr. Xavier Morató, associate director of clinical trials; and Dr. Pilar Sanz, neurologist .

From Ace we presented several studies focused on biomarkers and emerging treatments. Among the findings shared, studies on the biomarker pTau217 and the innovative treatment with bepranemab, both promising for the detection and management of early-stage Alzheimer's disease, were highlighted.

“CTAD is an excellent opportunity to showcase the results of our studies and establish collaborations that will undoubtedly shape the future of dementia research,” commented Dr. Boada.

Our participation in CTAD underscores Ace's commitment to advancing better diagnosis and treatment options for Alzheimer's disease, thereby improving the quality of life of patients and their families.

Ace:
News